NB 1008

Drug Profile

NB 1008

Alternative Names: Fluzone + 60%W805EC; Influenza mucosal vaccine - NanoBio; Intranasal nanoemulsion vaccine for influenza - NanoBio; Intranasal seasonal influenza vaccine - NanoBio; NanoStatmuscosal influenza vaccine; NB-1008; Transmucosal influenza vaccine - NanoBio

Latest Information Update: 18 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NanoBio Corporation
  • Class Influenza virus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza virus infections

Most Recent Events

  • 27 Mar 2013 NanoBio Corporation completes a phase I trial in Influenza virus infections (prevention, in volunteers) in USA (NCT01354379)
  • 23 Jan 2012 NanoBio Corporation completes enrolment in its phase I trial for Influenza virus infections (prevention, in volunteers) in USA (NCT01354379)
  • 13 May 2011 Phase-I clinical trials in Influenza virus infections in USA (Intranasal, spray)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top